Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark West Virginia Dupixent Prior Auth Coverag…
    Ask Trek AI about this page
    CurrentHighmark West VirginiaPolicy N/A

    Dupixent (dupilumab) prior authorization request - coverage criteria

    Customize your policy alerts

    Sign up for all Highmark West Virginia policy alerts

    Know when Highmark West Virginia releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This form governs prior authorization requests for Dupixent (dupilumab) across multiple labeled indications and is intended for providers requesting coverage for Highmark West Virginia members.

    Policy Summary
    PayerHighmark West Virginia
    PolicyDupixent (dupilumab) prior authorization request - coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the Dupixent prior authorization form with diagnosis, dosing, weight, clinical documentation, medication history, and prescriber signature.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleIndications on form

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    Presentation options
    28/84Day supply choices
    kgWeight collected

    Coverage criteria by indication

    Indication-level coverage

    Coverage is assessed per indication when the corresponding indication-specific criteria are met.

    Covered indications: Atopic dermatitis; eosinophilic esophagitis; asthma; chronic rhinosinusitis with nasal polyposis; prurigo nodularis; COPD; chronic spontaneous urticaria; bullous pemphigoid

    Provider must complete the section corresponding to the chosen indication and supply objective measures and prior therapy history.

    Moderate-to-severe atopic dermatitis

    Atopic dermatitis specific considerations

    Atopic dermatitis baseline requirements: Prescribed by a dermatologist, allergist, immunologist, or other appropriate specialist; therapeutic failure or intolerance to a generic topical corticosteroid, topical tacrolimus, or topical pimecrolimus; member incapable of applying topical therapies due to extent of BSA involvement OR severe atopic dermatitis with severely damaged skin; indicate if member is currently on Dupixent and, if so, whether there is a positive clinical response.

    If currently on Dupixent, provider must indicate positive clinical response to continue therapy.

    Eosinophilic esophagitis

    Eosinophilic esophagitis specific requirements

    EoE requirements: Esophageal eosinophil count >= 15 eos/hpf on esophageal biopsy; clinical symptoms of esophageal dysfunction (for example, dysphagia, food impaction, gastroesophageal reflux); history of EoE signs or symptoms; at least two episodes of dysphagia per week; therapeutic failure, intolerance, or contraindication to high‑dose proton‑pump inhibitor therapy (for example, omeprazole or pantoprazole 80 mg/day); indicate if member is currently on Dupixent and document histological remission or symptom response if applicable.>=15 eos/hpf

    Form captures histological remission and symptom response if currently on therapy.

    Moderate-to-severe asthma

    Asthma specific requirements

    Asthma requirements: Provide prebronchodilator FEV1; evidence of FEV1 reversibility >= 12% and 200 mL after albuterol OR a history of >=2 exacerbations requiring systemic corticosteroids (or >=1 hospitalization) in the prior 12 months; eosinophilic phenotype with blood eosinophils >= 150 cells/µL; inadequate control despite medium- or high-dose inhaled corticosteroids plus at least one additional controller; member will continue controller therapy while on Dupixent; indicate current Dupixent use and document clinical response measures (decreased rescue medication or oral corticosteroid use, decreased exacerbation frequency, increased pulmonary function, or symptom reduction) if applicable.FEV1 reversibility >=12% and 200 mL; eos >=150 cells/µL

    Also captures oral corticosteroid use and reductions in exacerbations/function as continuation criteria.

    Chronic rhinosinusitis with nasal polyposis (CRSwNP)

    Chronic rhinosinusitis with nasal polyposis (CRSwNP)

    CRSwNP requirements: Provide baseline bilateral nasal polyp score (0–8) and baseline nasal congestion score (0–3); therapeutic failure, intolerance, or contraindication to an intranasal corticosteroid and to a 14‑day course of oral corticosteroids; indicate current Dupixent use and document response (decrease in nasal polyp score or reduction in nasal congestion) if applicable.Nasal polyp score 0-8; congestion 0-3

    Form requests objective baseline scores (sum of left and right nostril scores).

    Prurigo nodularis

    Prurigo nodularis — indication-specific criteria

    Prurigo nodularis requirements: Prescribed by a dermatologist, allergist, immunologist, or other appropriate specialist; at least 10 identifiable nodular lesions; therapeutic failure, intolerance, or contraindication to one generic topical corticosteroid; member incapable of applying topical therapies due to extent of BSA involvement OR severely damaged skin; indicate current Dupixent use and document response (reduction in itch or lesion count) if applicable.>=10 nodules

    Form captures reduction in itch or lesion count if on therapy.

    Chronic obstructive pulmonary disease (COPD)

    Chronic obstructive pulmonary disease (COPD) — indication-specific criteria

    COPD requirements: Provide post‑bronchodilator FEV1 percent predicted; blood eosinophil count; mMRC dyspnea scale score; whether currently taking daily or alternate‑day oral corticosteroids; history of >=2 moderate exacerbations requiring systemic corticosteroids and/or antibiotics in the prior year OR >=1 severe exacerbation resulting in hospitalization or observation >24 hours; documentation that COPD is GOLD group E; inadequate symptom control despite >=3 months of triple therapy (LAMA + LABA + ICS) or intolerance/contraindication to those agents; indicate current Dupixent use and document response (reduction in COPD symptoms, improved exercise tolerance, delayed progression, or reduced exacerbations) if applicable.

    Form captures multiple objective COPD measures to support use.

    Chronic spontaneous urticaria (CSU)

    Chronic spontaneous urticaria (CSU) — indication-specific criteria

    CSU requirements: Therapeutic failure, intolerance, or contraindication to one second‑generation non‑sedating H1 antihistamine at maximum recommended doses (for example: cetirizine, desloratadine, levocetirizine); indicate current Dupixent use and document improvement in CSU symptoms while on therapy if applicable.

    Form asks about prior antihistamine failure.

    Bullous pemphigoid

    Bullous pemphigoid — indication-specific criteria

    Bullous pemphigoid requirements: Prescribed by a dermatologist, allergist, immunologist, or other appropriate specialist; therapeutic failure, intolerance, or contraindication to oral corticosteroids and to high‑ or super‑high‑potency topical corticosteroids; indicate current Dupixent use and document clinical response (disease control, reduction in relapses, improvement in symptoms, or reduction in oral corticosteroid use) if applicable.

    Form captures clinical response and reduction in oral steroid need.

    The prior authorization form does not list any explicit exclusions. The form asks the prescriber to specify the Dupixent product presentation and the diagnosis/ICD-10 code(s) but contains no section enumerating conditions or situations that are expressly excluded from coverage.

    The form itself does not define specific not medically necessary conditions. It requires the provider’s attestation that the requested services are medically indicated and necessary, and notes that payment is subject to member eligibility and that an authorization decision does not guarantee payment.

    Diagnosis, lab thresholds, and measurement values

    Requested diagnosis/ICD-10ICD-10
    none listedForm requests 'Diagnosis and/or ICD-10 codes(s):' but lists no specific codes
    Eosinophils per high power field (EoE) — >= 15 eos/hpf
    Eosinophil threshold (EoE)>= 15 eos/hpf on esophageal biopsy
    Clinical requirementClinical symptoms of esophageal dysfunction (eg, dysphagia, food impaction, GERD)
    Prior therapy requirementTherapeutic failure, intolerance, or contraindication to high‑dose PPI therapy
    FEV1 reversibility — >= 12% and 200 milliliters after albuterol
    Reversibility threshold>= 12% and >= 200 milliliters increase in FEV1 after albuterol
    Measure requestedPrebronchodilator FEV1 (percent) must be provided

    Submission and documentation requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Complete the Dupixent request form specifying the exact product requested, diagnosis/ICD-10 code(s), and dosing (induction and maintenance where applicable). Include prescriber information (physician name, NPI, phone, fax, address, city, state, zip, suite/building) and the physician signature and date.

    • Specify product: Dupixent 200mg/1.14ml syringe; Dupixent 300mg/2ml syringe; Dupixent 200mg/1.14ml pen; Dupixent 300mg/2ml pen
    • Provide diagnosis and ICD-10 code(s)
    • Include dosing schedule (induction and maintenance) and whether member is currently on Dupixent
    Step Therapy

    Step Therapy / Prior Treatment Failures

    Step therapy and prior treatment failures must be documented on the form. Indicate whether the member experienced therapeutic failure, intolerance, or has a contraindication to the specified prior therapies relevant to the diagnosis being treated.

    Initial therapy dosing and supply

    Initial therapy dosing

    Dosing and supply — provider must indicate product presentation, requested quantity, and day supply.

    Product selection and dosing: Provider must indicate product presentation (Dupixent 200 mg/1.14 mL or Dupixent 300 mg/2 mL; syringe or pen), whether induction dosing is required, number of pens/syringes requested, and requested day supply (28 days, 84 days, or other).

    Member weight is requested to support dosing where applicable.

    Requirements for continuing therapy

    Continuation therapy evidence

    Continuation therapy documentation requested for members already on Dupixent.

    Continuation response measures: If currently on Dupixent, provider must indicate clinical response measures such as decreased rescue medication or oral corticosteroid use, decreased frequency of severe exacerbations, increased pulmonary function, reduction in symptoms, decreased nasal polyp score or congestion, histological remission in EoE (<15 eos/hpf), reduction in itch or nodules, or reduction in relapses for bullous pemphigoid.

    Used to support ongoing therapy.

    Prior treatment and step requirements

    RequirementForm field / provider action
    Indicate prior therapeutic failure, intolerance, or contraindication to specified prior therapies (per indication)Select applicable prior therapy failures/intolerances on the form (examples: generic topical corticosteroid; generic topical tacrolimus; generic topical pimecrolimus; high‑dose PPI for EoE; intranasal corticosteroid or 14‑day oral corticosteroid for CRSwNP; second‑generation non‑sedating H1 antihistamine for CSU; oral corticosteroids or high‑potency topical corticosteroids for bullous pemphigoid)
    If currently on Dupixent, document clinical response to therapy when applicableCheck 'Yes' and select response items on the form (examples: decreased exacerbations or rescue medication use, increased pulmonary function, decreased nasal polyp score/congestion, histological remission in EoE, reduction in itch or nodules, reduction in relapses for bullous pemphigoid)
    Provider must complete the section corresponding to the chosen indication and supply objective measures and prior therapy historyComplete indication‑specific fields on the form (examples: eosinophil count ≥15 eos/hpf for EoE; baseline bilateral nasal polyp score 0–8 for CRSwNP; FEV1 and reversibility or exacerbation history for asthma; ≥10 nodules for prurigo nodularis)
    Provide medication history of other therapies tried and failedUse the Medication History section to list other medications the member has tried and failed and attach supporting clinical documentation as instructed

    Requested supply and quantity

    Dupixent (dupilumab) — Requested number of pens/syringes as provided by prescriber
    Quantity requestedRequested number of pens/syringes as provided by prescriber (entered on Maintenance Dosing section)
    Day supply optionsRequested day supply choices on form: 28 days, 84 days, or other
    Presentation selectionProvider must indicate product presentation (200 mg/1.14 mL or 300 mg/2 mL syringe/pen) when requesting quantity

    Site-of-care restrictions

    Note

    No explicit site‑of‑care restrictions on the form

    The form does not impose any explicit site‑of‑care restrictions; follow the standard submission and instructions for processing.

    • Use the standard fax or mail submission pathways listed on the form.
    • No separate site‑of‑care field or restriction is specified on the request form.

    Clinical background

    Dupixent (dupilumab) is requested across multiple inflammatory conditions on the form, including moderate-to-severe atopic dermatitis, eosinophilic esophagitis, asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, and bullous pemphigoid. The form collects indication-specific objective measures (for example, esophageal eosinophil counts, FEV1 and reversibility, blood eosinophils, nasal polyp score, mMRC score, and nodular lesion counts) and documents prior therapy history to support medical necessity and continuation of therapy when applicable.

    Clinical score definitions and scales

    Nasal Polyp Score — Sum of right and left nostril scores (each 0–4) for a total score 0–8
    DefinitionSum of right and left nostril scores (each scored 0–4) for a total score 0–8
    Per‑nostril scaleEach nostril scored 0 = no polyp to 4 = large polyp
    Use on formBaseline bilateral nasal polyp score (0–8) is requested to characterize nasal polyps
    mMRC dyspnea scale — Modified Medical Research Council dyspnea scale used to assess baseline functional disability due to dyspnea.
    Scale purposeModified Medical Research Council (mMRC) dyspnea scale assesses baseline functional disability due to dyspnea
    Form fieldForm requests the member's mMRC score for COPD assessment
    Policy Summary
    PayerHighmark West Virginia
    PolicyDupixent (dupilumab) prior authorization request - coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the Dupixent prior authorization form with diagnosis, dosing, weight, clinical documentation, medication history, and prescriber signature.
    SourceLink
    On This Page
    Coverage criteria by indicationDiagnosis, lab thresholds, and measurement valuesSubmission and documentation requirementsInitial therapy dosing and supplyRequirements for continuing therapyPrior treatment and step requirementsRequested supply and quantitySite-of-care restrictionsClinical backgroundClinical score definitions and scales
    Alternative asthma criteriaHistory of >=2 exacerbations requiring systemic corticosteroids or >=1 hospitalization in prior 12 months
    Asthma exacerbation history — >= 2 exacerbations requiring systemic corticosteroids in prior 12 months (or >=1 hospitalization)
    Exacerbation threshold>= 2 exacerbations requiring oral or injectable systemic corticosteroids in prior 12 months
    Hospitalization alternative>= 1 asthma exacerbation requiring hospitalization in prior 12 months (alternative criterion)
    DocumentationForm asks for history of exacerbations and current oral corticosteroid use
    Nasal Polyp Score (baseline) — 0-8 (sum of two nostrils)
    Score range0–8 (sum of right and left nostril scores)
    Per‑nostril scoringEach nostril scored 0–4; total = left + right
    UseBaseline bilateral nasal polyp score requested on form
    Member weight — kilograms (requested)
    Weight (requested)Member's weight in kilograms (required to support dosing)
    Dosing relevanceWeight is requested to support dosing where applicable (initial/maintenance) and selection of presentation
  1. Atopic dermatitis: document failure/intolerance to generic topical corticosteroids, topical tacrolimus, or topical pimecrolimus; note inability to apply topicals due to BSA when applicable
  2. Eosinophilic esophagitis: document failure/intolerance/contraindication to high‑dose PPI therapy
  3. Chronic rhinosinusitis with nasal polyposis: document failure/intolerance/contraindication to intranasal corticosteroid and to a 14‑day course of oral corticosteroids
  4. Chronic spontaneous urticaria: document failure/intolerance/contraindication to one second‑generation non‑sedating H1 antihistamine at maximum recommended doses
  5. Bullous pemphigoid: document failure/intolerance/contraindication to oral corticosteroids and high‑potency topical corticosteroids
  6. Documentation Required

    Submission Instructions

    Fax or mail the completed form with all required clinical documentation. Include the physician address (required for physician notification) and the prescriber's signature certifying the information is true and complete.

    • Fax to: 1-866-240-8123
    • Mail to: 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222
    • Submit a separate form for each medication request; print or type legibly in blue or black ink; the prescribing physician should generally complete the form
    Denial Risk

    Payment and Authorization Note

    Payment is subject to member eligibility. An authorization, if issued, does not guarantee payment.

    • The submitting provider certifies the information is true, accurate, and complete and that the requested services are medically indicated and necessary
    • Authorization decisions are independent of final payment determination based on member eligibility and benefits
    Context of usemMRC score used alongside post‑bronchodilator FEV1 and blood eosinophil count to support COPD indication